BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia

BERKELEY, Calif., and VANCOUVER, British Columbia, September 16, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announces that the Company will be presenting at the 2nd Annual Next Gen Immuno-Oncology Congress, taking place September 19-20, 2019 at Hilton Garden …

BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49

BERKELEY, Calif., and VANCOUVER, British Columbia, September 9, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has upsized and closed its previously-announced non-brokered private placement (the “Offering”) of common shares in the capital of the Company. Under …

BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019

BERKELEY, Calif., and VANCOUVER, British Columbia, August 27, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced it will be featured as a presenting company at the 21st Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright …

BriaCell Appoints Richard J. Berman to Board of Directors

BERKELEY, Calif., and VANCOUVER, British Columbia, August 12, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that it has appointed Mr. Richard J. Berman, JD, MBA, to its Board of Directors. Mr. Berman is a highly experienced corporate …

BriaCell Announces $350,000 Equity Investment by Board of Directors

BERKELEY, Calif., and VANCOUVER, British Columbia, July 23, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it intends to complete a non-brokered private placement of up to 5,000,000 common shares of the Company at a …

BriaCell’s Novel Technology and Clinical Data Published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

BERKELEY, Calif., and VANCOUVER, British Columbia, May 28, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that BriaCell’s clinical findings were published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings, a supplement to the …

BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders

BERKELEY, Calif., and VANCOUVER, British Columbia, May 13, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that the shareholders approved all matters addressed at the annual and special meeting (the “Meeting”) of the holders of common shares of …

BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston

BERKELEY, Calif., and VANCOUVER, British Columbia, April 23, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that BriaCell’s clinical findings will be published in the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings, a supplement to …

BriaCell’s Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity

• As presented at the American Association for Cancer Research (AACR) annual meeting: early efficacy data for the first six advanced breast cancer patients dosed with Bria-IMT™ in combination with KEYTRUDA® suggest additive or synergistic effects on tumor regression (“shrinkage”). • Findings support BriaCell’s hypothesis: KEYTRUDA® acts by “awakening” a component of the immune system, …

BriaCell Announces Clinical Trial Collaboration Agreement with Incyte

· BriaCell Therapeutics and Incyte have formed a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates · Under the agreement, Incyte will provide compounds from its development portfolio, including INCMGA00012, an anti-PD-1 monoclonal antibody, and epacadostat, an IDO1 inhibitor, for use in combination studies with BriaCell’s lead candidate, Bria-IMT™, …